Monitor the company's first commercial sales and revenue disclosures for Preservative-Free Ketamine in upcoming quarterly filings. The product addresses a known shortage, but the addressable market size and pricing are not disclosed.
Drug in focus
NRXP drug pipeline →Preservative-Free Ketamine
◆ Mixed Named in this 8-K- Impact
- Phase
- Approved (ANDA)
- Time to market
- Approved as of October 30, 2026. The company has ordered 5 million vials for launch inventory and is transitioning to commercial-stage operations.
- Next catalyst
- None dated
What to watchThe ANDA approval binary has passed. Watch for commercial launch execution (hospital formulary adoption, initial sales numbers) and the Q3 2026 earnings call on November 16 for revenue guidance. The bigger binary catalyst ahead is the NRX-100 NDA decision for suicidal depression (estimated PDUFA ~December 2026), which targets a much larger market opportunity than the generic ANDA product. Also monitor the FDA's decision on NRx's citizen petition to ban BZT-containing ketamine products, which could dramatically alter the competitive landscape.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 2 $2.17entry
- T+1 · 14d ago +3.23%α +2.93% · $2.24
- T+5 · 8d ago +9.68%α +9.60% · $2.38
- T+10 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NRx Pharmaceuticals announced FDA approval of its ANDA for Preservative-Free Ketamine, ahead of the November 10, 2026 GDUFA goal date. The product is a preservative-free formulation of ketamine manufactured in the U.S. with Nephron Pharmaceuticals, addressing a drug shortage. The company has commercial supply on hand and can now label and supply hospitals and clinics.
Key Facts
- FDA approved NRx's ANDA for Preservative-Free Ketamine on October 30, 2026, ahead of the November 10, 2026 GDUFA goal date.
- The product contains no benzethonium chloride (BZT), a preservative not designated as GRAS by the FDA.
- Ketamine injection has been in short supply since 2018 and is on the FDA drug shortage list.
- NRx has manufactured commercial supply on hand and can now label and supply American hospitals and clinics.
- Manufacturing is done in the U.S. with Nephron Pharmaceuticals in West Columbia, South Carolina using blow-fill-seal technology.
- NRx market cap is $115M; the company is a clinical-stage biopharma with no prior commercial revenue from this product.
Financial Impact
FDA approval of a drug on the shortage list with commercial supply on hand; no revenue or pricing data disclosed. The approval opens a new revenue stream for a pre-revenue company.
Risk Factors
- No financial data or revenue guidance provided in the filing; commercial success is unproven.
- The company is clinical-stage with no prior commercial revenue; execution risk in manufacturing and distribution.
- Competition from other ketamine suppliers may limit market share.
- The company's other pipeline candidates (NRX-100, NRX-101) remain in clinical development with regulatory and commercial risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-034284 |
| Exhibit: ex_1035048.htm | 0001437749-26-034284 |
| Document: 0001437749-26-034284-index-headers.html | 0001437749-26-034284 |
| Document: 0001437749-26-034284-index.html | 0001437749-26-034284 |
| Document: 0001437749-26-034284.txt | 0001437749-26-034284 |
Track record
22 reports on NRXP
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 9 of 12 went positive at some point.
Filters
- Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Viewing Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
- Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
- Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
- Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
- Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers